Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers.

Open Access CRIS of the University of Bern 2026 Open access

Read full text
Authors: Magno, Giulia, Rejeski, Kai, Rappa, Giulia, Stock, Sophia, Holzem, Alessandra, Landwehr, Maria, Seib, Maximilian, Kutsch, Nadine, Mammadova, Jamila, Mayer, Stephanie, Aumann, Shlomzion, Van Ham, Jonas
+23 more Ringelstein-Harlev, Shimrit, Velazquez, Giuliano Filippini, Wurm-Kuczera, Rebecca, Scholz, Julia Katharina, Greenbaum, Uri, Raj, Sandeep S, Shouval, Roni, Müller, Fabian, Chapuy, Bjoern, Schmid, Christoph, Beyar-Katz, Ofrat, Vergote, Vibeke Kj, Poeck, Hendrik, Dong, Ning, Holtick, Udo, Ram, Ron, Pabst, Thomas, Shumilov, Evgenii, Lenz, Georg, Iacoboni, Gloria, Barba, Pere, Bücklein, Veit L, Subklewe, Marion
DOI: 10.48620/92195
Cited by: 0

Abstract

T-cell-redirecting bispecific antibodies (bsABs) offer a novel therapeutic approach for relapsed/refractory large B-cell lymphoma (r/r LBCL). However, predictive biomarkers are needed to identify patients most likely to respond. As both bsAb and chimeric antigen receptor (CAR) T cells represent T cell-based therapies, we hypothesized that the established CAR-HEMATOTOX (HT) and InflaMix models-reflecting the degree of systemic inflammation-could be of prognostic utility for bsAb therapy. We applied both scores to a multicenter international cohort of 174 r/r LBCL patients treated with bsAb across 15 sites. Patients with a high HT score (≥3, 35%) displayed inferior median progression-free (PFS, 1.4 vs 7.4 months; p

Fields of Study & Subjects

CAR-T cell therapy research Monoclonal and Polyclonal Antibodies Research Cutaneous lymphoproliferative disorders research

Publication details

Journal / source
Open Access CRIS of the University of Bern
Publication date
10 March 2026
Language
EN